Quantifying Treatment Effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial
View ORCID ProfileAndrew A. Lover
doi: https://doi.org/10.1101/2020.03.22.20040949
Andrew A. Lover
Department of Biostatistics and Epidemiology, University of Massachusetts- Amherst, Amherst, MA

Data Availability
Data sources, statistical code, and supporting documents are available here: https://github.com/andrewlover/HCQ_AZ_COVID_19
Posted March 27, 2020.
Quantifying Treatment Effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial
Andrew A. Lover
medRxiv 2020.03.22.20040949; doi: https://doi.org/10.1101/2020.03.22.20040949
Subject Area
Subject Areas
- Addiction Medicine (175)
- Allergy and Immunology (421)
- Anesthesia (97)
- Cardiovascular Medicine (901)
- Dermatology (102)
- Emergency Medicine (257)
- Epidemiology (8797)
- Gastroenterology (405)
- Genetic and Genomic Medicine (1867)
- Geriatric Medicine (179)
- Health Economics (389)
- Health Informatics (1292)
- Health Policy (644)
- Hematology (207)
- HIV/AIDS (396)
- Medical Education (193)
- Medical Ethics (52)
- Nephrology (218)
- Neurology (1763)
- Nursing (104)
- Nutrition (267)
- Oncology (966)
- Ophthalmology (284)
- Orthopedics (107)
- Otolaryngology (177)
- Pain Medicine (118)
- Palliative Medicine (43)
- Pathology (265)
- Pediatrics (557)
- Primary Care Research (221)
- Public and Global Health (3992)
- Radiology and Imaging (655)
- Respiratory Medicine (536)
- Rheumatology (216)
- Sports Medicine (166)
- Surgery (197)
- Toxicology (37)
- Transplantation (107)
- Urology (80)